AU2005279537C1 - GLP-1 and exendin related invention - Google Patents

GLP-1 and exendin related invention Download PDF

Info

Publication number
AU2005279537C1
AU2005279537C1 AU2005279537A AU2005279537A AU2005279537C1 AU 2005279537 C1 AU2005279537 C1 AU 2005279537C1 AU 2005279537 A AU2005279537 A AU 2005279537A AU 2005279537 A AU2005279537 A AU 2005279537A AU 2005279537 C1 AU2005279537 C1 AU 2005279537C1
Authority
AU
Australia
Prior art keywords
exendin
glp
peptide derivatives
therapy
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005279537A
Other languages
English (en)
Other versions
AU2005279537B2 (en
AU2005279537A1 (en
Inventor
Martin Behe
Thomas Behr
Burkhard J. Goke
Martin Gotthardt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philipps Universitaet Marburg
Original Assignee
Philipps Universitaet Marburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philipps Universitaet Marburg filed Critical Philipps Universitaet Marburg
Publication of AU2005279537A1 publication Critical patent/AU2005279537A1/en
Application granted granted Critical
Publication of AU2005279537B2 publication Critical patent/AU2005279537B2/en
Priority to AU2012202855A priority Critical patent/AU2012202855B2/en
Publication of AU2005279537C1 publication Critical patent/AU2005279537C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
AU2005279537A 2004-09-03 2005-08-26 GLP-1 and exendin related invention Ceased AU2005279537C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012202855A AU2012202855B2 (en) 2004-09-03 2012-05-16 GLP-1 and exendin related invention

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004043153A DE102004043153B4 (de) 2004-09-03 2004-09-03 Erfindung betreffend GLP-1 und Exendin
DE102004043153.1 2004-09-03
PCT/DE2005/001503 WO2006024275A2 (de) 2004-09-03 2005-08-26 Erfindung betreffend glp-1 und exendin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012202855A Division AU2012202855B2 (en) 2004-09-03 2012-05-16 GLP-1 and exendin related invention

Publications (3)

Publication Number Publication Date
AU2005279537A1 AU2005279537A1 (en) 2006-03-09
AU2005279537B2 AU2005279537B2 (en) 2012-02-16
AU2005279537C1 true AU2005279537C1 (en) 2012-07-05

Family

ID=35970651

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005279537A Ceased AU2005279537C1 (en) 2004-09-03 2005-08-26 GLP-1 and exendin related invention

Country Status (16)

Country Link
US (2) US8268781B2 (OSRAM)
EP (3) EP2301962B1 (OSRAM)
JP (1) JP5047795B2 (OSRAM)
KR (1) KR101237152B1 (OSRAM)
CN (3) CN102358752B (OSRAM)
AT (1) ATE486090T1 (OSRAM)
AU (1) AU2005279537C1 (OSRAM)
BR (1) BRPI0515624A (OSRAM)
CA (2) CA2797666A1 (OSRAM)
DE (2) DE102004043153B4 (OSRAM)
HR (1) HRP20110061T1 (OSRAM)
MX (1) MX2007002455A (OSRAM)
NO (1) NO20071592L (OSRAM)
PL (2) PL2301962T3 (OSRAM)
RU (3) RU2489443C2 (OSRAM)
WO (1) WO2006024275A2 (OSRAM)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0612471A2 (pt) * 2005-05-05 2016-09-06 Cadila Healthcare Ltd novos compostos como agonistas glp-1
LT3456340T (lt) 2007-01-08 2022-05-10 The Trustees Of The University Of Pennsylvania Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui
KR20110043766A (ko) * 2008-09-20 2011-04-27 고쿠리츠 다이가쿠 호진 교토 다이가쿠 췌도 이미징용 분자 프로브 전구체 및 그의 사용
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
WO2010118034A2 (en) * 2009-04-06 2010-10-14 Board Of Regents, The University Of Texas System Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
JP5685401B2 (ja) * 2009-08-10 2015-03-18 国立大学法人京都大学 膵島イメージング用分子プローブ及びその前駆体、並びに、それらの使用
WO2011027584A1 (ja) * 2009-09-04 2011-03-10 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
WO2011040460A1 (ja) * 2009-09-30 2011-04-07 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
JP5700835B2 (ja) 2009-12-10 2015-04-15 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
CN101875700B (zh) * 2010-04-09 2012-09-26 无锡和邦生物科技有限公司 一种增加促胰岛素分泌肽融合蛋白生物活性的方法
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US9278146B2 (en) 2010-10-08 2016-03-08 Kyoto University Peptide derivative and use of the same
WO2012121746A2 (en) * 2011-03-09 2012-09-13 The General Hospital Corporation Imaging beta cell mass
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2729493B1 (en) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US8901484B2 (en) * 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
WO2013182217A1 (en) * 2012-04-27 2013-12-12 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI674270B (zh) * 2012-12-11 2019-10-11 英商梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
CN103344764B (zh) * 2013-06-19 2014-11-26 天津美德太平洋科技有限公司 胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
DE102014112747A1 (de) 2014-09-04 2016-03-10 Eberhard Karls Universität Tübingen Medizinische Fakultät Verwendung eines Quinoxalinderivats in einem bildgebenden Verfahren
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
SMT202100668T1 (it) 2015-05-22 2022-01-10 Univ Leland Stanford Junior Trattamento dell'ipoglicemia post-bariatrica con antagonisti del glp-1
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
AU2016372245B2 (en) 2015-12-14 2020-07-16 Antaros Medical Ab Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP7584894B2 (ja) 2016-11-21 2024-11-18 アイガー・バイオファーマシューティカルズ・インコーポレイテッド エキセンディン（９－３９）の緩衝製剤
JP7736315B2 (ja) 2020-03-31 2025-09-09 アンタロス メディカル アクティエボラーグ イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001144A1 (en) * 1989-07-20 1991-02-07 Sandoz Ltd Labeled polypeptide derivatives
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels
US6767887B1 (en) * 1996-06-05 2004-07-27 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
WO1999043705A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
WO1999043708A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
WO2000034331A2 (en) * 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
EP1175443A1 (en) * 1999-04-30 2002-01-30 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
SI1180121T1 (en) * 1999-05-17 2004-04-30 Conjuchem, Inc. Long lasting insulinotropic peptides
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1246638B2 (en) * 2000-01-10 2014-07-30 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of hypertriglyceridemia
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
KR20050049525A (ko) * 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Ｇｌｐ-1 유도체 및 그의 경점막 흡수형 제제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001144A1 (en) * 1989-07-20 1991-02-07 Sandoz Ltd Labeled polypeptide derivatives
US6767887B1 (en) * 1996-06-05 2004-07-27 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
WO2000069900A2 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001004156A1 (en) * 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Gotthardt, M. et al., Journal of Nuclear Medicine, 2000, 41 (5) Supplement, 9P, Abstract 31. *

Also Published As

Publication number Publication date
CN101010340B (zh) 2012-11-28
PL2301962T3 (pl) 2014-05-30
PL2070946T3 (pl) 2013-09-30
EP2070946A3 (de) 2009-09-09
EP2070946A2 (de) 2009-06-17
RU2010148446A (ru) 2012-06-10
CA2578252A1 (en) 2006-03-09
RU2489443C2 (ru) 2013-08-10
JP2008511557A (ja) 2008-04-17
RU2007112115A (ru) 2008-10-10
ATE486090T1 (de) 2010-11-15
DE502005010449D1 (de) 2010-12-09
CN102358752B (zh) 2014-07-30
AU2005279537B2 (en) 2012-02-16
WO2006024275A3 (de) 2006-11-30
EP1784422B1 (de) 2010-10-27
RU2486197C2 (ru) 2013-06-27
HRP20110061T1 (hr) 2011-02-28
CN102304179A (zh) 2012-01-04
RU2010148447A (ru) 2012-06-10
RU2420536C2 (ru) 2011-06-10
KR101237152B1 (ko) 2013-03-04
CN102358752A (zh) 2012-02-22
EP1784422A2 (de) 2007-05-16
DE102004043153A1 (de) 2006-03-23
US20090180953A1 (en) 2009-07-16
CA2797666A1 (en) 2006-03-09
CN101010340A (zh) 2007-08-01
EP2301962A2 (de) 2011-03-30
EP2070946B1 (de) 2013-05-29
EP2301962A3 (de) 2011-11-02
JP5047795B2 (ja) 2012-10-10
BRPI0515624A (pt) 2008-07-29
WO2006024275A2 (de) 2006-03-09
EP2301962B1 (de) 2013-10-30
AU2005279537A1 (en) 2006-03-09
MX2007002455A (es) 2007-10-10
NO20071592L (no) 2007-05-29
DE102004043153B4 (de) 2013-11-21
US8268781B2 (en) 2012-09-18
KR20070093960A (ko) 2007-09-19
US20130095037A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
AU2005279537B2 (en) GLP-1 and exendin related invention
Serganova et al. Human reporter genes: potential use in clinical studies
CZ386297A3 (cs) Multityrosinovaná somatostatinová analoga
CN102695527A (zh) 胰岛成像用分子探针及其使用
JP2001523257A (ja) カルシトニン受容体結合ペプチド
Ishizaki et al. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives
Carollo et al. State of the art and recent developments of radiopharmaceuticals for pancreatic neuroendocrine tumors imaging
EP0584256B1 (en) Compounds and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
AU2012202855B2 (en) GLP-1 and exendin related invention
EP4171662A1 (en) Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes
Mansi et al. Radiolabeled peptides for cancer imaging and therapy: from bench-to-bedside
US6395255B1 (en) Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy
Vallabhajosula Theranostics in Neuroendocrine Tumors
Nikolopoulou et al. 99mTc targeting of sst2-expressing tumors by tetraamineoctreotide: first results in CA20948 cells and rat models
TWI288751B (en) Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
Lazniekova et al. Studies in rats on octreotide labelled with Ga-67: A potential radiopharmaceutical agent for the treatment of somatostatin receptor-positive tumours

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 FEB 2012.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 23 FEB 2012

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired